Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 242

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance

Open access
O'Shannessy, Daniel J., Yu, Gordon, Smale, Robert, Fu, Yao-Shi, Singhal, Sunil, Thiel, Robert P., Somers, Elizabeth B., Vachani, Anil · 2012 · Oncotarget

Abstract

Daniel J. O’Shannessy 1 , Gordon Yu 3 , Robert Smale 5 , Yao-Shi Fu 5 , Sunil Singhal 4 , Robert P. Thiel 6 , Elizabeth B. Somers 1 , and Anil Vachani 2 1 Department of Diagnostics Development, Morphotek, Inc., Exton, PA 2 Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 3 Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia, PA 4 Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA 5 Laboratory Corporation of America, Los Angeles, CA 6 Thiel Statistical Consulting, Oxford, CT Received: April 24, 2012; Accepted: April 25, 2012; Published: April 29, 2012; Keywords: folate receptor alpha, FRA, non-small cell lung cancer, adenocarcinoma, prognosis, immunohistochemistry Correspondence: Daniel J. O’Shannessy, email: // // Abstract With the advent of targeted therapies directed towards folate receptor alpha, with several such agents in late stage clinical development, the sensitive and robust detection of folate receptor alpha in tissues is of importance relative to patient selection and perhaps prognosis and prediction of response. The goal of the present study was to evaluate the expression of folate receptor alpha in non-small cell lung cancer specimens to determine its frequency of expression and its potential for prognosis. The distribution of folate receptor alpha expression in normal tissues as well as its expression and relationship to non-small cell lung cancer subtypes was assessed by immunohistochemistry using tissue microarrays and fine needle aspirates and an optimized manual staining method using the recently developed monoclonal antibody 26B3. The association between folate receptor alpha expression and clinical outcome was also evaluated on a tissue microarray created from formalin fixed paraffin embedded specimens from patients with surgically resected lung adenocarcinoma. Folate receptor alpha expression was shown to have a high discriminatory capacity for lung adenocarcinomas versus squamous cell carcinomas. While 74% of adenocarcinomas were positive for folate receptor alpha expression, our results found that only 13% of squamous cell carcinomas were FRA positive (p<0.0001). In patients with adenocarcinoma that underwent surgical resection, increased folate receptor alpha expression was associated with improved overall survival (Hazard Ratio 0.39, 95% CI 0.18-0.85). These data demonstrate the diagnostic relevance of folate receptor alpha expression in non-small cell lung cancer as determined by immunohistochemistry and suggest that determination of folate receptor alpha expression provides prognostic information in patients with lung adenocarcinoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.519

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 242

Metadata

Authors
O'Shannessy, D. J., Yu, G., Smale, R., Fu, Y.-S., Singhal, S., Thiel, R. P., Somers, E. B., & Vachani, A.
Venue
Oncotarget
Published
2012-04-29
Volume
3
Issue
4
Pages
414-425
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1507264290
Cited by
242
References
2
FWCI
12.33
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.